Pharmamarketeer

ViiV seeks EU marketing nod for cabotegravir in combo with rilpivirine as first monthly, injectable treatment for HIV

ViiV Healthcare, the global specialist HIV company majority owned by GSK, with Pfizer Inc. and Shionogi Limited as shareholders, announced the submission of a marketing authorisation application (MAA) to the

Advertentie(s)
Geen nieuws missen?
Volg de duizenden farma professionals die Pharmamarkteer.nl via e-mail lezen

Uw inschrijving is gelukt.
Bedankt!
Naar Pharmamarkteer.nl